The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3
Authors:
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 515 (2) , 332-338
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81201868, 81471532, 81560030, 31371380)
This publication has 39 references indexed in Scilit:
- Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic StateCell, 2012
- The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple MyelomaJournal of Clinical Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effectBMC Medicine, 2009
- p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsBritish Journal of Haematology, 2008
- c‐Jun N‐terminal kinase regulates mitochondrial bioenergetics by modulating pyruvate dehydrogenase activity in primary cortical neuronsJournal of Neurochemistry, 2007
- Phosphorylation of the 6-Phosphofructo-2-Kinase/Fructose 2,6-Bisphosphatase/PFKFB3 Family of Glycolytic Regulators in Human CancerClinical Cancer Research, 2005
- Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERKOncogene, 2004
- A Kinetic Study of Pyrophosphate: Fructose‐6‐Phosphate Phosphotransferase from Potato TubersEuropean Journal of Biochemistry, 1982
- On the Origin of Cancer CellsScience, 1956